"There has been steady progress in ovarian cancer screening… with refinement of screening modalities and strategies as well as the conduct of large-scale trials in both the high risk and general population," says Professor Ian Jacobs, Vice President and Dean of the Faculty of Medical and Human Sciences at the University of Manchester and Meeting Chair. "This two-day meeting will review the state-of-the-art in risk prediction and screening for ovarian cancer as well as prospects for the future, novel approaches and implications for therapy."
An enriching opportunity for GPs, epidemiologists, gynaecologists, medical oncologists, radiologists and ultrasonographers alike, the International Conference on Ovarian Cancer Screening 2011 will feature compelling sessions on Lead Time of Screening by Professor Ian Jacobs, Insights from BRCA Mutation Carriers by Professor Christopher P. Crum and The Status of Stratification by Dr. Paul Pharoah. Other sessions include Differential Diagnostics, Defining Risk, General Population Screening – Insights from Trials, High Risk Population Screening – Update from Current Trials, Natural History of Ovarian Cancer and Biomarkers and Screening. The conference will close with a consensus workshop for all delegates.
Sponsored by Roche, Fujirebio Diagnostics and Antibodies-Online, the conference will be held at the Royal College of Physicians in the heart of London, UK. Accommodations have been arranged at the four-star Meliá White House Hotel. Registration is available online until November 28 and onsite registration is available online. The registration fees include admission to the conference's lectures and demonstrations by renowned experts, take-home course materials for future reference, lunch and refreshments.
To register, please visit the conference website: www.ovariancancermeeting.com